Researchers say if their results are confirmed through further study they are optimistic the approach could be used to treat ...

In their effort to answer a decades-old biological question about how the hepatitis B virus (HBV) is able to establish infection of liver cells, research led by Memorial Sloan Kettering Cancer Center ...

In their effort to answer a decades-old biological question about how the hepatitis B virus (HBV) is able to establish ...

With several drugs in use that inhibit the hepatitis B virus polymerases (nucleos(t)ide analogues (or NUCs)), some argue that new direct-acting antiviral drugs, and new NUCs in particular ...

Larger antigens, including antigen in immune complexes, can be presented to B cells on the surface of cells, such as dendritic cells, macrophages and follicular dendritic cells (FDCs). These ...

The duration of hepatitis B surface antigen (HBsAg) exposure (indicated by the patient’s age), rather than the quantity of HBsAg, was associated with the level of anti-HBV immune response, in ...

Study: AGA Clinical Practice Guideline on the Prevention and Treatment of Hepatitis B Virus Reactivation in ... who are either positive for the HBV surface antigen (HBsAg) or HBV core antibody ...

Brelovitug is a fully human immunoglobulin G1 monoclonal antibody that targets hepatitis B virus surface antigen (HBsAG). By binding to HBsAg, brelovitug is expected to neutralize and clear hepatitis ...

Hepatitis B (sometimes referred to as hep B) is a liver infection caused by the hepatitis B virus (HBV). It typically causes symptoms like stomach pain, dark urine, fatigue, fever, jaundice (yellowing ...